Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMMXNASDAQ:OKURNASDAQ:ORGSNASDAQ:TNYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMMXImmix Biopharma$2.24-6.3%$2.08$1.26▼$3.00$66.63M0.31155,648 shs139,384 shsOKUROnKure Therapeutics$2.37-2.1%$2.49$1.70▼$20.00$32.69M0.42110,947 shs70,678 shsORGSOrgenesis$1.80+9.1%$2.09$0.87▼$10.80$8.64M0.548,528 shs4,785 shsTNYATenaya Therapeutics$0.59+1.5%$0.50$0.36▼$4.06$94.10M2.912.64 million shs3.37 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMMXImmix Biopharma-6.28%-4.68%+7.18%+24.44%+11.44%OKUROnKure Therapeutics-2.07%-10.57%+5.33%-53.07%+236,999,900.00%ORGSOrgenesis+9.09%-7.69%-10.45%-35.77%+179,999,900.00%TNYATenaya Therapeutics+1.49%-0.74%+32.80%-7.78%-81.42%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMMXImmix Biopharma3.1342 of 5 stars3.53.00.00.02.53.30.6OKUROnKure Therapeutics2.5624 of 5 stars3.70.00.00.00.62.51.3ORGSOrgenesis1.5161 of 5 stars0.04.00.04.40.60.00.0TNYATenaya Therapeutics3.0323 of 5 stars3.53.00.00.00.04.21.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMMXImmix Biopharma 3.00Buy$7.00212.50% UpsideOKUROnKure Therapeutics 3.33Buy$32.331,264.28% UpsideORGSOrgenesis 0.00N/AN/AN/ATNYATenaya Therapeutics 3.00Buy$6.25964.55% UpsideCurrent Analyst Ratings BreakdownLatest ORGS, TNYA, IMMX, and OKUR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025IMMXImmix BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.005/9/2025TNYATenaya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/30/2025OKUROnKure TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/25/2025TNYATenaya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/31/2025TNYATenaya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMMXImmix BiopharmaN/AN/AN/AN/A$0.48 per shareN/AOKUROnKure TherapeuticsN/AN/AN/AN/A$7.78 per shareN/AORGSOrgenesis$662K13.05N/AN/A($6.58) per share-0.27TNYATenaya TherapeuticsN/AN/AN/AN/A$1.07 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMMXImmix Biopharma-$21.61M-$0.70N/AN/AN/AN/A-130.02%-86.33%8/11/2025 (Estimated)OKUROnKure Therapeutics-$52.67M-$5.26N/AN/AN/AN/A-49.13%-45.72%8/12/2025 (Estimated)ORGSOrgenesis-$55.36MN/A0.00∞N/A-3,827.81%N/A-130.18%8/6/2025 (Estimated)TNYATenaya Therapeutics-$111.13M-$1.16N/AN/AN/AN/A-92.20%-74.53%8/14/2025 (Estimated)Latest ORGS, TNYA, IMMX, and OKUR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025TNYATenaya Therapeutics-$0.18-$0.24-$0.06-$0.24N/AN/A5/6/2025Q1 2025OKUROnKure Therapeutics-$1.41-$1.19+$0.22-$1.19N/AN/A3/24/2025Q4 2024IMMXImmix Biopharma-$0.25-$0.16+$0.09-$0.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMMXImmix BiopharmaN/AN/AN/AN/AN/AOKUROnKure TherapeuticsN/AN/AN/AN/AN/AORGSOrgenesisN/AN/AN/AN/AN/ATNYATenaya TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMMXImmix BiopharmaN/A1.801.80OKUROnKure TherapeuticsN/A11.1811.17ORGSOrgenesisN/A0.070.07TNYATenaya TherapeuticsN/A6.686.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMMXImmix Biopharma11.26%OKUROnKure Therapeutics90.98%ORGSOrgenesis22.56%TNYATenaya Therapeutics90.54%Insider OwnershipCompanyInsider OwnershipIMMXImmix Biopharma55.40%OKUROnKure Therapeutics2.30%ORGSOrgenesis5.66%TNYATenaya Therapeutics48.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMMXImmix Biopharma927.88 million12.43 millionOptionableOKUROnKure TherapeuticsN/A13.51 million13.20 millionN/AORGSOrgenesis1504.80 million4.53 millionNo DataTNYATenaya Therapeutics110162.67 million83.53 millionOptionableORGS, TNYA, IMMX, and OKUR HeadlinesRecent News About These CompaniesTenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Rating of "Buy" by AnalystsJune 12, 2025 | marketbeat.comHead-To-Head Survey: Tenaya Therapeutics (NASDAQ:TNYA) versus Alpha Cognition (NASDAQ:ACOG)June 12, 2025 | americanbankingnews.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Sees Large Growth in Short InterestJune 2, 2025 | marketbeat.comTenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)May 16, 2025 | finanznachrichten.deTenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)May 15, 2025 | globenewswire.comWhy Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 5.10%May 15, 2025 | aaii.comTenaya Therapeutics to Present Five Abstracts on Innovative Heart Disease Gene Therapies at ASGCT 2025 Annual MeetingMay 15, 2025 | nasdaq.comTenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual MeetingMay 13, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL), Stevanato Group (STVN) and Tenaya Therapeutics (TNYA)May 11, 2025 | theglobeandmail.comWe're A Little Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn RateMay 10, 2025 | finance.yahoo.comTenaya Therapeutics Reports Q1 2025 Financial ResultsMay 8, 2025 | tipranks.comTenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 7, 2025 | finance.yahoo.comWhy Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Up 5.03%May 2, 2025 | aaii.comWhy Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 6.21%April 30, 2025 | aaii.comH.C. Wainwright maintains Buy on Tenaya Therapeutics stockApril 26, 2025 | investing.comWhy Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Up 6.36%April 26, 2025 | aaii.comTenaya announces interim data from ongoing RIDGE studyApril 25, 2025 | markets.businessinsider.comTenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025April 24, 2025 | globenewswire.comTenaya Slashes a Third of Workforce to Fund Development of Cardio Gene TherapiesApril 1, 2025 | biospace.comWhy Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 11.06%April 1, 2025 | aaii.comTenaya data further builds TN-201 profile, says H.C. WainwrightApril 1, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeORGS, TNYA, IMMX, and OKUR Company DescriptionsImmix Biopharma NASDAQ:IMMX$2.24 -0.15 (-6.28%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.22 -0.02 (-0.89%) As of 06/20/2025 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.OnKure Therapeutics NASDAQ:OKUR$2.37 -0.05 (-2.07%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.37 0.00 (-0.21%) As of 06/20/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.Orgenesis NASDAQ:ORGS$1.80 +0.15 (+9.09%) As of 06/20/2025 02:12 PM EasternOrgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.Tenaya Therapeutics NASDAQ:TNYA$0.59 +0.01 (+1.49%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.59 0.00 (-0.19%) As of 06/20/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
